Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26191125
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Int+J+Clin+Exp+Pathol
2015 ; 8
(5
): 4332-43
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis
#MMPMID26191125
Wang R
; Yan Z
; Wu X
; Ji K
; Wang H
; Zang B
Int J Clin Exp Pathol
2015[]; 8
(5
): 4332-43
PMID26191125
show ga
Hyperlipidemic pancreatitis (HP) is a serious inflammatory disease with very high
mortality and multiple organ injuries including renal injury. Rosiglitazone
(Ros), an agonist of peroxisome proliferator activated receptor-? (PPAR-?), was
reported to show a protective role against pancreatitis. However, whether Ros has
an effect on renal injury caused by HP is not yet clear. In the present study,
the function of Ros was explored using ELISA, RT-PCR, western blot, PAS staining
and immunohistochemistry. Results of this study showed that Ros could inhibit the
activation of NF-?B and MAPK P38 signaling pathways, relieve inflammatory
response and inhibit cell apoptosis, thus attenuating renal injury caused by HP.
This study suggested that Ros might be a promising drug for the treatment of
renal injury caused by HP and also laid theoretical foundation for the
development of renal injury treatment.
|Acute Kidney Injury/*etiology/*prevention & control
[MESH]
free
free
free
